![](/img/cover-not-exists.png)
Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
Luke, J. J., Hodi, F. S.Volume:
18
Language:
english
Journal:
The Oncologist
DOI:
10.1634/theoncologist.2012-0391
Date:
June, 2013
File:
PDF, 1.27 MB
english, 2013